Lacerda L, Faria APD, Fontana V, Moreno H, Sandrim V. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
Arq Bras Cardiol 2015;
105:168-75. [PMID:
26039662 PMCID:
PMC4559126 DOI:
10.5935/abc.20150060]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Background
Despite the increased evidence of the important role of matrix metalloproteinases
(MMP-9 and MMP‑2) in the pathophysiology of hypertension, the profile of these
molecules in resistant hypertension (RHTN) remains unknown.
Objectives
To compare the plasma levels of MMP-9 and MMP-2 and of their tissue inhibitors
(TIMP-1 and TIMP-2, respectively), as well as their MMP-9/TIMP-1 and MMP-2/TIMP-2
ratios, between patients with controlled RHTN (CRHTN, n=41) and uncontrolled RHTN
(UCRHTN, n=35). In addition, the association of those parameters with clinical
characteristics, office blood pressure (BP) and arterial stiffness (determined by
pulse wave velocity) was evaluate in those subgroups.
Methods
This study included 76 individuals diagnosed with RHTN and submitted to physical
examination, electrocardiogram, and laboratory tests to assess biochemical
parameters.
Results
Similar values of MMP-9, MMP-2, TIMP-1, TIMP-2, and MMP-9/TIMP-1 and MMP-2/TIMP-2
ratios were found in the UCRHTN and CRHTN subgroups (P>0.05). A significant
correlation was found between diastolic BP (DBP) and MMP-9/TIMP-1 ratio (r=0.37;
P=0.02) and DPB and MMP-2 (r=-0.40; P=0.02) in the UCRHTN subgroup. On the other
hand, no correlation was observed in the CRHTN subgroup. Logistic regression
models demonstrated that MMP-9, MMP-2, TIMP-1, TIMP-2 and their ratios were not
associated with the lack of BP control.
Conclusion
These findings suggest that neither MMP-2 nor MMP-9 affect BP control in RHTN
subjects.
Collapse